Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ

Journal of the National Cancer Institute - Monographs

Volumn , Issue 41, 2010, Pages 145-149

  Shapiro wright, Hilary M ^a   Julian, Thomas B ^a,b,c,d  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b NSABP Foundation Inc   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Allegheny Breast Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ARTICLE; AXILLA; BREAST CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CARCINOMA IN SITU; CLINICAL TRIAL (TOPIC); EDEMA; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE DISSECTION; LYMPHEDEMA; MAMMOGRAPHY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; NERVE INJURY; OUTCOME ASSESSMENT; PARESTHESIA; PARTIAL MASTECTOMY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENTINEL LYMPH NODE BIOPSY; SEROMA; SHOULDER PAIN; WOUND INFECTION; ADJUVANT THERAPY; ADULT; BREAST TUMOR; CANCER STAGING; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; REVIEW; RISK; SENSITIVITY AND SPECIFICITY; STATISTICS; TREATMENT OUTCOME; UNNECESSARY PROCEDURE;

ADULT; AXILLA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME; UNNECESSARY PROCEDURES;

EID: 79952201565     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgq026     Document Type: Article

References (50)

1. Fentiman IS. The dilemma of in situ carcinoma of the breast. Int J Clin Pract. 2001;55(10):680-683.
2. Silverstein MJ, Roser RJ, Gierson ED, et al. Axillary lymph node dissection for intraductal breast carcinoma-is it indicated? Cancer. 1987;59(10):1819-1824.
3. Baxter NN, Virnig BA, Durham SB, Tuttle TM. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2004;96(6):443-448.
4. Ashikari R, Huvos AG, Snyder RE. Prospective study of noninfiltrating carcinoma of the breast. Cancer. 1977;39(2):435-439.
5. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW. Breast carcinoma in situ: a retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg. 1985;150(1):44-51.
6. Winchester DP, Menck HR, Osteen RT, Kraybill W. Treatment trends for ductal carcinoma in situ of the breast. Ann Surg Oncol. 1995;2(3):207-213.
7. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275(12):913-918.
8. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441-452.
9. Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14(8):2202-2208.
10. Trisal V, Qian D, Wagman LD. Axillary recurrence in DCIS: is axillary lymphadenectomy warranted? Am Surg. 2004;70(10):876-880.
11. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer. 1990;66(1):102-108.
12. Kinne DW, Perrek JA, Osborne MP, et al. Breast carcinoma in situ. Arch Surg. 1989;124(1):33.
13. Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003;138(3):309.
14. Jackman RJ, Nowels KW, Rodriguez-Soto J, et al. Stereotactic, automated, large core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology. 1999;210(3):799-805.
15. Lee CH, Carter D, Philpotts LS, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology. 2000;217(2):466-470.
16. Pandelidis S, Heilman D, Jones D, et al. Accuracy of 11 gauge vacuum-assisted core biopsy of mammographic breast lesions. Ann Surg Oncol. 2003;20(1):43-47.
17. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001;218(2):497-502.
18. Pendas S, Dauway E, Giuliano R, et al. Sentinel node biopsy in DCIS patients. Ann Surg Oncol. 2000;7(1):15-20.
19. Klauber-DeMore N, Tan LK, Lieberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol. 2000;7(9):636-642.
20. Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001;67(6):513-519.
21. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005;200(4):516-526.
22. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Ductal carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50(7):1309-1314.
23. Hardman PD, Worth A, Lee U, Baird RM. The risk of occult invasive breast cancer after excisional biopsy showing in-situ ductal carcinoma of comedo pattern. Can J Surg. 1989;32(1):56-60.
24. Wilkie C, White L, Dupont E, et al. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ. Am J Surg. 2005;190(4):563-566.
25. Goyal A, Douglas-Jones A, Monypenny I, et al. Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ? Analysis of 587 cases. Breast Cancer Res Treat. 2006;98(3):311-314.
26. Dillon MF, McDermott EW, Quinn CM, et al. Predictors of invasive disease in breast cancer when core needle biopsy demonstrates DCIS only. J Surg Oncol. 2006;93(7):559-563.
27. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
28. Mabry H, Giulino AE, Silverstein MJ. What is the value of axillary dissection or sentinel node biopsy in patients with ductal carcinoma in situ? Am J Surg. 2006;192(4):455-457.
29. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg. 2008;247(2):315.
30. Murphy CD, Jones JL, Javid SH, et al. Do sentinel node micrometastases predict recurrence risk in ductal carcinoma in situ and ductal carcinoma in situ with microinvasion? Am J Surg. 2008;196(4):566-568.
31. Lara JF, Young SM, Velilla RE, et al. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow up. Cancer. 2003;98(10):2105-2113.
32. Julian TB, Krag D, Brown A, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients [abstract]. Breast Cancer Res Treat. 2004;88:S11-S12.
33. Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881-888.
34. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13(4):491-500.
35. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599.
36. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546-553.
37. Temple LK, Baron R, Cody HS III, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol. 2002;9(7):654-662.
38. Haid A, Kuehn T, Konstantinuk P, et al. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. Eur J Surg Oncol. 2002;28(7):705-710.
39. Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312-4321.
40. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657-3663.
41. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245(3):452-461.
42. Tan JC, McCready DR, Easson AM, et al. Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy. Ann Surg Oncol. 2007;14(2):638-645.
43. Dominguez FJ, Golshan M, Black DM, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol. 2007;15(1):268-273.
44. Langer S, Guenther JM, Haigh PI, et al. Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma. Am J Surg. 2004;70(10):881-885.
45. Sabel MS, Degnim A, Wilkins EG, et al. Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer. Am J Surg. 2004;187(6):673-678.
46. Intra M, Veronesi P, Gentilini OD, et al. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007;95(2):175-189.
47. Carter BA, Jensen RA, Simpson JF, et al. Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Pathol. 2000;113(2):259-265.
48. Bleiweiss IJ, Nagi CS, Jaffer S. Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 2006;24(13):2013-2018.
49. Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-7720.
50. Schwartz GF, Giuliano AE, Veronesi U, et al. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94(10):2532-2551.